ABIOMED, Inc. (ABMD)
(Delayed Data from NSDQ)
$271.75 USD
+6.98 (2.64%)
Updated May 3, 2019 04:00 PM ET
After-Market: $271.72 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$271.75 USD
+6.98 (2.64%)
Updated May 3, 2019 04:00 PM ET
After-Market: $271.72 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Why Abiomed (ABMD) Could Beat Earnings Estimates Again
by Zacks Equity Research
Abiomed (ABMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
AngioDynamics (ANGO) Q1 Earnings, Revenues Lag Estimates
by Zacks Equity Research
AngioDynamics (ANGO) registers strong revenue growth in the Med Tech business in first-quarter fiscal 2023.
Walgreens (WBA) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Walgreens (WBA) is expected to have registered growth in Q4 in its U.S. retail pharmacy business, banking on demand for vaccinations and tests amid the ongoing series of contagious virus spread.
Edwards Lifesciences (EW) TAVR Sales Strong Amid Macro Issues
by Zacks Equity Research
Edwards Lifesciences (EW) expects full-year 2022 underlying sales growth in the mid-single-digit range on the back of strength in demand for products used in more intense surgeries.
Reasons to Retain Veeva Systems (VEEV) Stock in Your Portfolio
by Zacks Equity Research
Veeva Systems' (VEEV) slew of strategic deals raises optimism about the stock.
Neogen (NEOG) Q1 Earnings Top Estimates, Operating Margin Dips
by Zacks Equity Research
Neogen's (NEOG) allergen and environmental sanitation product lines decline due to reduced buying patterns from customers and supply chain disruptions of certain products.
Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Stock Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woes persist.
Abiomed (ABMD) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Abiomed (ABMD) possesses solid growth attributes, which could help it handily outperform the market.
Here's Why You Should Retain Inari Medical (NARI) Stock Now
by Zacks Equity Research
Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, dependency on the wide adoption of products is a woe.
Intuitive Surgical (ISRG) Up After da Vinci SP's Japan Approval
by Zacks Equity Research
Intuitive Surgical (ISRG) gains approval in Japan for its single-port robotic surgical system, da Vinci SP. It will enable surgeons to provide minimally invasive experience for complex procedures.
Abiomed (ABMD) Posts Impellas Positive Study Results in Japan
by Zacks Equity Research
Abiomed's (ABMD) latest multi-center, multi-society study of Impella-supported patients is expected to significantly improve patient outcomes.
Abiomed's (ABMD) Impella-Related Research Gets FDA Clearance
by Zacks Equity Research
Abiomed's (ABMD) latest regulatory clearances for clinical research of Impella heart pumps in AMI cardiogenic shock patients are expected to significantly improve patient outcomes.
3 Reasons to Hold Abiomed (ABMD) Stock in Your Portfolio
by Zacks Equity Research
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
Implied Volatility Surging for Abiomed (ABMD) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Abiomed (ABMD) stock based on the movements in the options market lately.
Abiomed's (ABMD) Impella Favored by Latest Study Result
by Zacks Equity Research
Abiomed's (ABMD) Impella-supported high-risk PCI leads to significant improvements in cardiovascular patient outcomes, per latest study.
Abiomed (ABMD) Q1 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Abiomed's (ABMD) strength in Impella product revenues drives its Q1 top line.
Abiomed (ABMD) Q1 Earnings Top Estimates
by Zacks Equity Research
Abiomed (ABMD) delivered earnings and revenue surprises of 15.74% and 0.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Medical Device Stocks Earnings on Aug 4: BDX, ABMD, AMN & DOCS
by Debanjana Dey
The Medical Device companies' Q2 results are likely to reflect strength in customer demand. Let's see how BDX, ABMD, AMN and DOCS are placed ahead of their earnings releases.
Abiomed (ABMD) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven Q1 sales.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Abiomed (ABMD) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Abiomed (ABMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Abiomed (ABMD) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Abiomed (ABMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why You Should Hold on to Abiomed (ABMD) Stock For Now
by Zacks Equity Research
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Reasons to Retain Abiomed (ABMD) Stock in Your Portfolio For Now
by Zacks Equity Research
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.